ライフサイエンスコーパス: OPG

1 OPG also improves muscle strength in mouse models of Duc

2 OPG is a decoy receptor for RANKL, thereby increasing BM

3 OPG is known to be a high-affinity heparan sulfate (HS)-

4 OPG levels upon simultaneous stimulation with Pam3CSK4 a

5 OPG levels were measured in serum or in plasma.

6 OPG preference was greater for fixed partial denture pla

7 OPGs and orbitofacial neurofibromas are clinically diver

8 OPGs are a common manifestation of NF1 and can cause sig

9 OPGs may enlarge in later childhood and beyond such that

10 Serum IL-1beta, OPG, and BALP levels revealed no significant difference

11 served in plasma levels of sRANKL (P=0.205), OPG (P=0.249), and sRANKL/OPG ratio (P=0.123) for the in

12 588; radiographs and OFS had kappaw = 0.542 (OPG kappaw = 0.555 and I-O kappaw = 0.521).

13 imal models suggest that IL-1b, TNF-a, IL-6, OPG and RANKL may mediate periodontitis in diabetes.

14 The expression of wild type GATA-3 activated OPG mRNA and protein expression, while the expression of

15 Although the total amounts of GCF albumin, OPG, IL-17A, and IL-17A/F were similar in the study grou

16 ldren 10 years or younger with NF1 and/or an OPG.

17 Children with an OPG (sporadic or secondary to neurofibromatosis type 1)

18 Production of IL-6, IL-8, MCP-1, and OPG was significantly increased by Poly I:C or Pam3CSK4

19 -8, RANK, and RANKL and increased BMP-2 and OPG levels in the periodontal tissue.

20 lcification (fibroblast growth factor-23 and OPG [osteoprotegerin]), 3 inflammatory biomarkers (tumor

21 nflammatory response (IP-10, IL-8, IL-6, and OPG), endothelial dysfunction (sVCAM-1 and sICAM-1), and

22 cantly promoted RANKL expression in ABCs and OPG in DPCs.

23 evelopment causing strabismic amblyopia, and OPG) were difficult to treat adequately and tended to ca

24 High levels of serum calcium and OPG are significantly associated with the progression of

25 se and preference of utilisation of CBCT and OPG by various dental practitioners in their clinical pr

26 -sectional study was carried out on CBCT and OPG data of 620 different cases treated by different den

27 investigate the levels of TRAIL DR4, DR5 and OPG receptors generating promising insights on the possi

28 RANKL increased and OPG decreased in P group and 100 mg/kg luteolin increase

29 at 40 and 104 degrees C), the heated OP and OPG oils showed the highest oxidative stability.

30 The association between PP and OPG remained significant after adjusting for multiple po

31 compared to other dental practitioners, and OPG was advocated for FPD planning, whereas CBCT was adv

32 ume at the beginning of pregnancy, RANKL and OPG appeared to influence breast volume with a mean incr

33 RANKL and OPG concentrations were estimated in peri-implant crevic

34 RANKL and OPG concentrations were increased in the OF group at 3 m

35 present in root dentin with robust RANKL and OPG expression.

36 ive RT-PCR showed up-regulation of RANKL and OPG, with a 128% increase in RANKL/OPG ratio in bgn(-/0)

37 and samplings, serum and GCF TOS, RANKL, and OPG levels were determined by a novel automatic colorime

38 , Hes 1, Hey 1, TNF-alpha, IL-17, RANKL, and OPG) was determined by reverse transcriptase - real-time

39 cTRAILR2 in primary neurons and of TRAIL and OPG in OPCs.

40 een recombinant human (rhTRAIL) variants and OPG.

41 te that the therapeutic efficacy of the anti-OPG antibody approach in the presence of standard of car

42 A and colocalization of reactivities to anti-OPG and anti-gp100 (HMB45) antibodies in LAM lung nodule

43 In this study, children with NF1-associated OPG whose examination signs and symptoms were normal had

44 rm follow-up in children with NF1-associated OPGs has not been reported previously.

45 th MDD had significant decreases in baseline OPG/RANKL ratio and in plasma OPN levels.

46 Both OPG and denosumab increased limb force proportionally to

47 ural deafness, and renal (HDR) syndrome - by OPG therapy.

48 At the multivariate analysis, serum calcium, OPG, and estimated glomerular filtration rate were the o

49 Circulating OPG levels are also important biomarkers of various clin

50 t into the genetic regulation of circulating OPG levels.

51 gerin (OPG)-immunoglobulin fragment complex (OPG-Fc) completely restore the function of fast-twitch e

52 S interaction in bone remodeling, we created OPG knock-in mice (opg (AAA) ).

53 Using a HS binding-deficient OPG mutant, we further show that in an osteoblast/bone m

54 significantly induced mRNAs for TRAIL, DR5, OPG, and mDcTRAILR2 in primary neurons and of TRAIL and

55 The expression of TRAIL, DR5, OPG, and mDcTRAILR2 was significantly increased after HI

56 0 kb upstream of the TNFRSF11B gene encoding OPG and another new locus on chromosome 17q11.2 were sig

57 During the course of injury, endogenous OPG appears to suppress the effects of RANKL.

58 prevented by the co-treatment with exogenous OPG.

59 MCP-1 production, which was not observed for OPG.

60 ent group demonstrated stronger staining for OPG than the estrogen-deficient group (P < 0.05).

61 OEBFs prepared from OPG-knock-out mice exhibited a similar effect, indicatin

62 g children with and without vision loss from OPGs.

63 al detachment) or the afferent system (e.g., OPG), and 12 patients had correctable refractive errors.

64 Furthermore, serum and GCF OPG concentrations were lower in the periodontitis group

65 01; P <0.0001; P = 0.032, respectively), GCF OPG (P = 0.036), and serum and saliva sRANKL (P <0.0001)

66 , aged 4-28 years) had optic pathway glioma (OPG) in addition to OFNF.

67 Optic Pathway Glioma (OPG) is a relatively common brain tumour in childhood; h

68 pe 1 (NF1)-associated optic pathway gliomas (OPGs) and a follow-up period of at least 10 years in a c

69 Optic pathway gliomas (OPGs) and orbitofacial plexiform neurofibromas are two o

70 50% of children with optic pathway gliomas (OPGs) experience visual impairment, and few regain their

71 g young children with optic pathway gliomas (OPGs) for visual deterioration can be difficult owing to

72 Children with optic pathway gliomas (OPGs) frequently experience vision loss from their tumor

73 The management of optic pathway gliomas (OPGs) remains controversial.

74 s type 1 (NF1) and/or optic pathway gliomas (OPGs).

75 in the optic pathway (optic pathway gliomas, OPGs), especially in children with the neurofibromatosis

76 a pre-specified objective performance goal (OPG).

77 In the etidronate-treated group, OPG expression was significantly expressed and osteoclas

78 g analysis revealed that upon binding of HS, OPG undergoes a dramatic conformational change, resultin

79 resent here three lines of evidence that HS, OPG, and RANKL form a stable ternary complex.

80 However, the molecular detail of HS-OPG interaction remains poorly understood, which hinders

81 Importantly, we identify OPG as a HIF target gene capable of directing osteoblast

82 Most important, OPG-Fc combined with a low dose of formoterol, a member

83 However, despite marked improvements, OPG-Fc was not as effective in preventing the loss of fu

84 whereas the increase in mTEC availability in OPG-deficient (Tnfrsf11b(-/-)) mice impacts the intrathy

85 ovement pressure zone, without any change in OPG expression.

86 lity of producing oxygen, the key element in OPG wastewater treatment.

87 Mutations in OPG are involved in a variety of human diseases.

88 No differences were observed in OPG expression among groups.

89 AT1R silencing also increased OPG gene expression in HGF only.

90 ATV reduced RANKL and DKK-1 and increased OPG, WNT10b, and beta-catenin expressions and BALP activ

91 in P group and 100 mg/kg luteolin increased OPG and decreased RANKL levels significantly.

92 mice exhibited a similar effect, indicating OPG-independent inhibition.

93 expression of TFAP2B and the RANK inhibitor, OPG, in human breast cancer correlate and are associated

94 rable receptor activator of NF-kappaB ligand/OPG ratio, in addition to known anti-inflammatory and pr

95 Moreover, by mapping OPG expression to a subset of Aire(+) mTEC, our data sho

96 The mutated OPG is incapable of binding to HS but binds RANKL normal

97 We demonstrate that female Nf1-OPG mice exhibit greater retinal ganglion cell (RGC) los

98 In addition, female Nf1-OPG mice have threefold more microglia than their male c

99 ects the retinal abnormalities in female Nf1-OPG mice.

100 outcome, we leveraged Nf1 optic glioma (Nf1-OPG) mice.

101 , as ovariectomy, but not castration, of Nf1-OPG mice normalizes RGC survival and RNFL thickness.

102 ith PGE2 stimulation, reduced RANKL, but not OPG, expression.

103 ggesting that the antiresorption activity of OPG requires HS.

104 lineage cells, which facilitates binding of OPG to membrane-anchored RANKL.

105 In this study, 12 children with diagnosis of OPG before 6 years of age received a comprehensive stand

106 saccharide is able to induce dimerization of OPG monomers with a stoichiometry of 1:1.

107 likely function of the C-terminal domains of OPG is to bind cell surface heparan sulfate (HS), but th

108 functions of the three C-terminal domains of OPG remain uncertain.

109 ut the function of the N-terminal domains of OPG, which is responsible for binding to RANKL, the exac

110 n of CTX and induced increased expression of OPG in unstressed animals with PD.

111 also produced OPG, as shown by expression of OPG mRNA and colocalization of reactivities to anti-OPG

112 resumably, HS could regulate the function of OPG and affect how it inhibits RANKL.

113 imated that over half of the heritability of OPG levels could be explained by all variants examined i

114 rophage co-culture system, immobilization of OPG by HS at the osteoblast cell surface substantially l

115 ecretion without affecting PTH inhibition of OPG expression, and it does so by blocking HDAC4 proteas

116 c muscles but is rescued by the injection of OPG-Fc.

117 cells secrete OPG at high levels and lack of OPG causes sensorineural hearing loss in addition to the

118 Gene expression and protein levels of OPG were enhanced by Poly I:C, but by lesser extent than

119 pothesized that these cellular mechanisms of OPG may be involved in the growth and proliferation of l

120 tiple myeloma cell lines, in the presence of OPG secreted by stromal cells.

121 ng increase for RANKL and TRAP; reduction of OPG and leukocytosis, which were significantly prevented

122 In order to study the regulation of OPG expression, we conducted a database search on regula

123 w of Col2a1-Opg mice, suggesting the role of OPG in blocking the differentiation of early mesenchymal

124 o investigate the biological significance of OPG-HS interaction in bone remodeling, we created OPG kn

125 we report mapping of the HS-binding site of OPG.

126 rtments and that represent direct targets of OPG-mediated control.

127 tantially lowers the inhibitory threshold of OPG toward RANKL.

128 ebral arteriopathy risk with the presence of OPGs.

129 Recent advances in the treatment of OPGs include chemotherapeutic, radiation-based, and surg

130 sphatidylethanolamine and glucose added oil (OPG).

131 slational levels, and it showed no effect on OPG expression in calvarial osteoblasts.

132 jection of anti-RANKL antibody (P < 0.05) or OPG-Fc (P < 0.01), but not L6-Fc, into rat gingival papi

133 on of optic nerve disease due to glaucoma or OPG and to the possibility that vision might be improved

134 Young children with NF1 and/or OPGs were frequently unable to complete recognition acui

135 clinical trial for children with NF1 and/or OPGs.

136 Osteoprotegerin (OPG) is a key regulator of bone remodeling.

137 Osteoprotegerin (OPG) is a marker and regulator of arterial calcification

138 Osteoprotegerin (OPG) is increased within serum and lesions of patients w

139 Osteoprotegerin (OPG) is involved in bone homeostasis and tumor cell surv

140 Osteoprotegerin (OPG), a decoy receptor secreted by osteoblasts, is a maj

141 Osteoprotegerin (OPG), a secreted decoy receptor for receptor activator o

142 Osteoprotegerin (OPG), a soluble receptor of the cytokine TNF-related apo

143 Interleukin (IL)-1beta, osteoprotegerin (OPG), and bone-specific alkaline phosphatase (BALP) seru

144 -kappa B ligand (RANKL); 2) osteoprotegerin (OPG); 3) interleukin (IL)-6; and 4) tumor necrosis facto

145 ibroblast growth factor 23, osteoprotegerin (OPG), fetuin A, and clinical and biochemical parameters.

146 pabeta ligand (sRANKL), and osteoprotegerin (OPG) at baseline (the date of initiation of anti-HCV the

147 kappa B ligand (RANKL) and osteoprotegerin (OPG) immunohistochemistry was carried out, and the RANKL

148 necrosis factor-alpha, and osteoprotegerin (OPG) in HGF and HPLF.

149 -17E, IL-17F, IL-17A/F, and osteoprotegerin (OPG) in women with rheumatoid arthritis (RA), osteoporos

150 r-kappaB ligand (RANKL) and osteoprotegerin (OPG) levels and RANKL/OPG ratios in serum and gingival c

151 F-kappaB ligand (RANKL) and osteoprotegerin (OPG) production by ST2 cells, despite MLO-Y4 cells suppo

152 F-kappaB ligand (RANKL) and osteoprotegerin (OPG) signaling in osteocytes was not studied in sheep.

153 -kappaB ligand (RANKL), and osteoprotegerin (OPG) that modulate bone homeostasis.

154 factor kappa-B (RANKL) and osteoprotegerin (OPG) to diagnose healthy peri-implant condition (HI), pe

155 ), RANK ligand (RANKL), and osteoprotegerin (OPG) were also investigated by immunohistochemistry to a

156 -kappaB ligand (RANKL), and osteoprotegerin (OPG) were analyzed in the furcation area of mandibular m

157 r-kappaB ligand (RANKL) and osteoprotegerin (OPG) were assessed by enzyme-linked immunosorbent assay

158 kappaB ligand (RANKL), and osteoprotegerin (OPG) were determined by immunohistochemistry.

159 actant protein (MCP)-1, and osteoprotegerin (OPG) were measured with qPCR and ELISA.

160 ession of RANKL, M-CSF, and osteoprotegerin (OPG).

161 its competitive antagonist osteoprotegerin (OPG) were analyzed by ELISA, quantitative polymerase cha

162 (RANKL) and its antagonist osteoprotegerin (OPG) were measured prospectively before gestational week

163 upregulated mRNA levels for osteoprotegerin (OPG) in comparison to PLAC (P < 0.05).

164 pression but >2-fold higher osteoprotegerin (OPG) expression than donor-matched ABCs, yielding a RANK

165 ntly higher RANKL and lower osteoprotegerin (OPG) mRNA and increased RANKL:OPG ratio.

166 effects on bone metabolism, osteoprotegerin (OPG), a soluble member of the tumor necrosis factor fami

167 ly conserved ectodomains of osteoprotegerin (OPG) and decoy receptor 3, other two secreted forms of T

168 ES increased expression of osteoprotegerin (OPG) and the OPG/RANKL ratio.

169 ctor-kappa B (RANKL) and of osteoprotegerin (OPG) were evaluated by immunofluorescent staining.

170 ntly enhanced expression of osteoprotegerin (OPG) without inducing change in receptor activator of NF

171 Serum levels of osteoprotegerin (OPG), a decoy receptor for RANKL, steadily increased ove

172 ed that daily injections of osteoprotegerin (OPG)-immunoglobulin fragment complex (OPG-Fc) completely

173 gh the direct regulation of osteoprotegerin (OPG).

174 and and decreased levels of osteoprotegerin (OPG).

175 Elevated ratio of osteoprotegerin (OPG)/receptor activator of nuclear factor-kappa B ligand

176 kappa-B ligand (RANKL)-RANK-osteoprotegerin (OPG) signaling associated with bone resorption.

177 RANK), RANK-ligand (RANKL), osteoprotegerin (OPG), and osteocalcin was performed.

178 ctor kappaB ligand (RANKL), osteoprotegerin (OPG), and tartrate-resistant acid phosphatase (TRAP) wer

179 tor-kappa B ligand (RANKL), osteoprotegerin (OPG), and tartrate-resistant acid phosphatase (TRAP).

180 ctor-kappaB ligand (RANKL), osteoprotegerin (OPG), tartrate-resistant acid phosphatase (TRAP), and ac

181 ctor-kappaB ligand (RANKL), osteoprotegerin (OPG), wingless (WNT) 10b, dickkopf-related protein 1 (DK

182 or kappaBeta ligand (RANKL)/osteoprotegerin (OPG) (2.5 +/- 0.7-fold, p < 0.001) ratio.

183 (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) axis and expression of the transcriptional regulato

184 of NF-kappaB ligand (RANKL)/osteoprotegerin (OPG), tumor necrosis factor alpha (TNF-alpha), and IL-1b

185 d the TRAIL decoy receptors osteoprotegerin (OPG), mDcTRAILR1, and mDcTRAILR2 were determined.

186 ative ratios of sclerostin, osteoprotegerin (OPG), and receptor activator of nuclear factor-kappaB li

187 tor-kappaB ligand (sRANKL), osteoprotegerin (OPG), a proliferation-inducing ligand (APRIL), B-cell ac

188 or-kappa B ligand (sRANKL), osteoprotegerin (OPG), B-cell activating factor (BAFF), and a proliferati

189 luble RANK ligand (sRANKL), osteoprotegerin (OPG), cathepsin-K, and sclerostin.

190 rs of bone inflammation-the osteoprotegerin (OPG)-RANK-RANKL system or osteopontin (OPN)-play a role

191 nd (RANKL) activates, while osteoprotegerin (OPG) inhibits, osteoclastogenesis.

192 ], bone sialoprotein [BSP], osteoprotegerin [OPG] and receptor activator of NF-KB ligand [RANKL]).

193 nd bone metabolism markers (osteoprotegerin [OPG], osteocalcin, procollagen type I N-terminal propept

194 stic increase in the preference of CBCT over OPG in recent times.

195 We report 4 cases of pediatric OPGs (2 neurofibromatosis type 1-related and 2 sporadic

196 Oxygenic photogranules (OPGs), spherical aggregates comprised of phototrophic an

197 Similarly, in Pparb-/-, OPG increased muscle volume and force, while also normal

198 a showed that among the dental practitioners OPG was more commonly ordered by general dentists (31%)

199 study showed that general dentists preferred OPG and CBCT compared to other dental practitioners, and

200 LAM lung nodules also produced OPG, as shown by expression of OPG mRNA and colocalizati

201 the in vivo function of chondrocyte-produced OPG in osteoclast formation and postnatal bone growth ha

202 KL antibody, osteoprotegerin fusion protein (OPG-Fc), or a control fusion protein (L6-Fc) into gingiv

203 he investigation, 143 panoramic radiographs (OPGs) and 77 intra-oral radiographs (I-Os) were evaluate

204 cell fusion and activation by the RANKL/RANK/OPG and ATP-P2RX7-IL1 pathways; and (3) regulatory mecha

205 Linking the RANKL/RANK/OPG pathway with breast volume changes supports further

206 ecules - including IL-1, IL-6, IL-17, RANKL, OPG, and CCL2 - modulate probiotic action.

207 d osteocyte TNF-alpha, interleukin-6, RANKL, OPG, and sclerostin corresponded with higher osteoclast

208 Systemic levels of RANKL, OPG, and inflammatory cytokines (interleukin-8, granuloc

209 ast volume at the start of pregnancy, RANKL, OPG, and other factors was used to predict breast volume

210 ting the osteoclast activation via the RANKL-OPG axis, without interfering with bone anabolism.

211 on than donor-matched ABCs, yielding a RANKL/OPG ratio of 41:1 (ABCs:DPCs).

212 increased the expression of RANKL and RANKL/OPG ratio by mesenchymal stem cells at 2 h.

213 decrease in the osteoclast number and RANKL/OPG ratio in periodontal lesions.

214 nomous increase in SOST/sclerostin and RANKL/OPG ratio in the setting of unloading.

215 ) and osteoprotegerin (OPG) levels and RANKL/OPG ratios in serum and gingival crevicular fluid (GCF)

216 nt results reveal that TOS, RANKL, and RANKL/OPG values are systemically and locally increased in per

217 Serum and GCF TOS, RANKL, and RANKL/OPG values were higher in the periodontitis groups compa

218 nd it helps in restoring the decreased RANKL/OPG ratio in adult mice.

219 blished that chondrocytes also express RANKL/OPG and support osteoclast formation.

220 ast differentiation through expressing RANKL/OPG cytokines.

221 The global RANKL/OPG ratio in the spine after 8 months of steroid and die

222 All test groups presented higher RANKL/OPG(+) cells than the control group around ligated/unlig

223 RANKL and OPG, with a 128% increase in RANKL/OPG ratio in bgn(-/0)fmod(-/-) TMJs.

224 deficient osteoclasts had an increased RANKL/OPG ratio, providing a positive feedback loop that incre

225 nt of osteolytic activity, while a low RANKL/OPG ratio is often observed in inactive lesions.

226 flammatory cytokines directly modulate RANKL/OPG expression and consequently drive lesion progression

227 nd activity by increasing the ratio of RANKL/OPG in osteoblasts.

228 ong effector cells and their impact on RANKL/OPG balance and lesion outcome.

229 We mainly focused on RANKL/OPG signalling, the TNF and TNF receptor superfamilies a

230 r of NF-kappaB ligand/osteoprotegerin (RANKL/OPG) ratio as the primary determinant of osteolytic acti

231 The perturbed RANKL/OPG ratio in RRV-infected OBs may therefore contribute t

232 arising due to imbalances in the RANK/RANKL/OPG molecular pathway, and due to the progressive weaken

233 The infection alters the RANK/RANKL/OPG signalling dynamics that regulates osteoblasts and o

234 , assessment of the osteocyte-specific RANKL/OPG ratio showed that the steroid-induced osteoporosis i

235 t signaling molecules that include the RankL/OPG axis and the Sost/Dkk1/Wnt axis, among others.

236 Differences in the RANKL/OPG Axis in vivo, and RANKL-induced maturation of osteoc

237 in level may be more reliable than the RANKL/OPG ratio as a diagnostic and prognostic marker of perio

238 eep model of osteoporosis to study the RANKL/OPG ratio correlation to the method of osteoporosis indu

239 dontal disease in rats, decreasing the RANKL/OPG ratio in gingival connective tissue and reducing alv

240 The RANKL/OPG ratio was also disrupted in mice infected with RRV;

241 istochemistry was carried out, and the RANKL/OPG ratio was calculated.

242 The RANKL/OPG ratio was disrupted in the synovial fluid of RRV pat

243 The RANKL/OPG ratio was significantly lower in healthy individuals

244 density of inflammatory cells and the RANKL/OPG ratio were significantly lower (P </=0.05) than in P

245 teoprotegerin (OPG) mRNA and increased RANKL:OPG ratio.

246 f GATA-3 or a GATA-3 shRNA construct reduced OPG mRNA and protein levels.

247 t that HS plays an active role in regulating OPG-RANKL interaction and osteoclastogenesis.

248 modeling by direct actions on bone, rescuing OPG production and restoring a favorable receptor activa

249 Sclerostin, OPG, and RANKL levels were measured by enzyme-linked imm

250 The sclerostin/OPG and sclerostin/RANKL ratios were significantly lower

251 that cochlear spiral ganglion cells secrete OPG at high levels and lack of OPG causes sensorineural

252 we propose that the HS immobilizes secreted OPG at the surface of osteoblasts lineage cells, which f

253 Serum OPG concentrations were significantly higher in the simv

254 Serum OPG was significantly higher in LAM patients than in nor

255 nally analyzed the association between serum OPG and PP in a prevalent cohort of 969 KTX patients (me

256 vastatin is associated with increasing serum OPG concentrations, and this could have a protective eff

257 ) scores, and GCF APRIL, serum sRANKL, serum OPG, and sRANKL concentrations in TM groups (P <0.05).

258 We conclude that serum OPG is independently associated with pulse pressure in k

259 Furthermore, IL-3 increases the serum OPG level in adult mice.

260 PP was positively correlated with serum OPG (rho = 0.284, p < 0.001).

261 sRANKL, OPG, and IL-17 levels were determined by enzyme-linked i

262 iva, and serum levels of IL-6, IL-8, sRANKL, OPG, BAFF, and APRIL were determined by enzyme-linked im

263 results are suggestive of a role of sRANKL, OPG, and sclerostin as prognostic biomarkers in peri-imp

264 differences in GCF concentrations of sRANKL, OPG, IL-17A, IL-17E, IL-17F, and IL-17A/F.

265 Concentrations of RANK, sRANKL, OPG, and sclerostin were significantly increased in pati

266 sRANKL (P=0.205), OPG (P=0.249), and sRANKL/OPG ratio (P=0.123) for the interaction between time and

267 Serum sRANKL, sRANKL/OPG, and IL-17A/IL-17E ratios were significantly higher,

268 The sRANKL/OPG ratios were significantly higher in the RA group tha

269 Stronger OPG immunolabeling and weaker RANKL immunolabeling were

270 Targeting OPG with a therapeutic antibody is a potential treatment

271 at treatment with a human antibody targeting OPG can attenuate pulmonary vascular remodelling associa

272 vantages of CBCT over 2D imaging techniques (OPG).

273 Based on these data, it appears that OPG may have tumor-promoting roles in the pathogenesis o

274 Our results demonstrated that OPG expression in chondrocyte increases bone mass in the

275 ur data provide strong genetic evidence that OPG-HS interaction is indispensable for normal bone home

276 Here we tested the hypothesis that OPG is associated with increased pulse pressure.

277 ne and cardiac tissues, we hypothesized that OPG-Fc, a bone and skeletal muscle protector, acts syner

278 Herein, we show that OPG stimulated proliferation of cells cultured from expl

279 The OPG-RANK-RANKL system plays the principal role in determ

280 expression of osteoprotegerin (OPG) and the OPG/RANKL ratio.

281 Ketamine significantly increased both the OPG/RANKL ratio and plasma OPN levels, and significantly

282 We discuss engineering the OPG process based on photogranules' size, promoting the

283 th TSC2 loss of heterozygosity expressed the OPG receptors, receptor activator of NF-kappaB ligand, s

284 atory elements in the promoter region of the OPG gene, and identified two potential GATA-3 binding si

285 We conclude that the OPG-RANK-RANKL system and the OPN system play important

286 nfidence bound: 29.9%) versus 43.0% with the OPG (p < 0.0001).

287 splays a significantly decreased affinity to OPG.

288 netically to make it incapable of binding to OPG.

289 high effectiveness and diminished binding to OPG.

290 7E ratios were significantly higher, whereas OPG concentrations were significantly lower in the RA gr

291 5) only for non-smokers at 6 months, whereas OPG was not significant (P >0.05).

292 n in HMOBs in a dose-dependent manner, while OPG protein remained similar to baseline.

293 e 17q11.2 were significantly associated with OPG variation.

294 Children with OPG are at moderate risk of neuropsychological impairmen

295 Children with OPG exhibited high within-patient variability and modera

296 Coincubation with OPG, the decoy receptor for RANKL, attenuated osteogenic

297 Given that most patients with OPG-related visual impairment will show modest or no vis

298 igratory phenotype in PASMCs stimulated with OPG is mediated via the Fas receptor and that treatment

299 bevacizumab-based treatment in children with OPGs.

300 er layer thickness inversely correlates with OPGs and decreased vision.